Twist Bioscience (TWST) Income from Continuing Operations (2017 - 2026)

Twist Bioscience (TWST) has reported Income from Continuing Operations for 10 consecutive years, with -$35.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 271.98% year-over-year to -$35.1 million in Q2 2026; TTM through Jun 2026 was -$136.7 million, a 60.44% decrease from a year earlier, with the FY2025 full-year figure at -$77.7 million, up 62.8% from the prior year.
• Income from Continuing Operations was -$35.1 million for Q2 2026 at Twist Bioscience, up from -$44.0 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $20.4 million in Q2 2025 and troughed at -$85.6 million in Q2 2024.
• A 5-year average of -$42.9 million and a median of -$43.5 million in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations jumped 123.82% in 2025 and slumped 271.98% in 2026, its largest moves.
• Over 5 years, Income from Continuing Operations stood at -$41.8 million in 2022, then decreased by 2.83% to -$43.0 million in 2023, then rose by 26.53% to -$31.6 million in 2024, then rose by 3.3% to -$30.6 million in 2025, then fell by 14.72% to -$35.1 million in 2026.
• The last three Income from Continuing Operations figures came in at -$35.1 million (Q2 2026), -$44.0 million (Q1 2026), and -$30.6 million (Q4 2025), per Business Quant data.